Drug General Information (ID: DDIC4VMJH1)
Drug Name			Moricizine		Drug Info		Atazanavir		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiarrhythmic Agents				Anti-Hiv Agents
Structure

Mechanism of Moricizine-Atazanavir Interaction (Severity Level: Major)
Increased risk of atrioventricular block Click to Show/Hide Mechanism Graph
Drug Name		Moricizine				Atazanavir
Mechanism		Delay atrioventricular conduction				Delay atrioventricular conduction
Key Mechanism Factor 1
		Factor Name		Atrioventricular block
		Factor Description		Atrioventricular block is a type of cardiac conduction block that occurs when the electrical signal from the atria to the ventricles is impaired. In an Atrioventricular block, this electrical signal is either delayed or completely blocked. When the signal is completely blocked, the ventricles produce their own electrical signal to control the heart rate. The heart rate produced by the ventricles is much slower than that produced by the sinus node.
Mechanism Description		Increased risk of atrioventricular block by the combination of Moricizine and Atazanavir

Recommended Action
Management		Caution is advised if atazanavir is used concomitantly with other agents that prolong the PR interval, particularly those that are metabolized by CYP450 3A4 (e.g., verapamil), since atazanavir is an inhibitor of that isoenzyme.

References
1	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
2	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.